Skip to main content
USH Blog Image

USH1F Research

Gene: PCDH15
Year Identified: 2001

Each research project listed below will include a graphic of the research continuum. The gold box indicates where this project falls on the continuum, illustrating its progress towards reaching people living with Usher syndrome, from "Bench to Bedside."

Click here to learn more about the different stages in the research continuum.

Zebrafish Model for USH1F

Research Continuum Graphic. Research in Pre-clinical stage. Sections shown in grey: Basic & Translational, Clinical trials: Phase I, Phase II, Phase III, Treatments-Phase IV. Highlighted in yellow: Pre-Clinical.
Profile Picture of Dr. Monte Westerfield

Monte Westerfield, Ph.D.: 
Institute of Neuroscience at University of Oregon
Westerfield and his team at the Institute of Neuroscience and Department of Biology at the University of Oregon are focusing on creating zebrafish models of multiple Usher syndrome mutations including USH1F. The Usher 1F Collaborative has funded the creation of a zebrafish model with USH1F R245X mutation that is carried by approximately 2% of those with Ashkenazi Jewish descent. Westerfield and his team, including Jennifer Phillips Ph.D. are now beginning the testing of drugs on the zebrafish that have potential to halt or slow the progression of vision loss. 
Dr. Monte Westerfield's Lab Page


Mouse Model with USH1F

Research Continuum Graphic. Research in Pre-clinical stage. Sections shown in grey: Basic & Translational, Clinical trials: Phase I, Phase II, Phase III, Treatments-Phase IV. Highlighted in yellow: Pre-Clinical.
Profile Picture of Dr. Zubair Ahmed

Zubair Ahmed, Ph.D.: 
University of Maryland School of Medicine
Ahmed and his team at the University of Maryland have developed a mouse model of the most prevalent USH1F mutation. They are now using the mouse model to test potential gene therapies. Additionally, in collaboration with Dr. Westerfield they are also testing drug therapies. He is also working to develop a mini gene for gene replacement for USH1F.  


Gene Therapy for USH1F

Research Continuum Graphic. Research in Pre-clinical stage. Sections shown in grey: Basic & Translational, Clinical trials: Phase I, Phase II, Phase III, Treatments-Phase IV. Highlighted in yellow: Pre-Clinical.
Profile photo of Dr. Edwin Stone

Edwin Stone, M.D., Ph.D.:
University of Iowa
Stone and his team at the University of Iowa are working to develop a cure for USH1F along with other types of retinitis pigmentosa. They are working to halt further retinal degeneration from USH1F through gene replacement and to repair damaged retinal photoreceptor cells with new cells made from the patient's own skin cells with the goal of a clinical trial once safety and efficacy are determined.
The University of Iowa Institute for Vision Research


Gene Replacement Therapy for USH1F

Research Continuum Graphic: Research in Basic/Translational stage. Highlighted in yellow: Basic/Translational. All other subsequent sections shown in grey: Pre-Clinical, Clinical Trials Phase I, Phase II, and Phase III, and Treatments-Phase IV.
Profile Picture of Dr. Livia Carvalho

Livia Carvalho, Ph.D.: 
University of Western Australia
Carvalho and team at University of Western Australia are collaborating with Zubair Ahmed Ph.D, from University of Maryland to develop gene replacement therapy for USH1F. She has developed a dual vector gene replacement therapy, which. Dr. Ahmed. is testing for efficacy on the USH1F mouse model. 
Dr. Livia Carvalho's Lab Page


Developing a Split Dual Vector System for Gene Replacement

Research Continuum Graphic: Research in Basic/Translational stage. Highlighted in yellow: Basic/Translational. All other subsequent sections shown in grey: Pre-Clinical, Clinical Trials Phase I, Phase II, and Phase III, and Treatments-Phase IV. Research C
Profile Picture of Dr. Leah Byrne

Leah Byrne, Ph.D.: 
University of Pittsburgh
Foundation Fighting Blindness Individual Investigator Research Award Recipient
Byrne and team at the University of Pittsburgh are developing. a split gene dual vector system for gene replacement. Her unique approach increases the efficiency of viral vector co-infection, increasing efficacy of large gene expression. Once completed Zubair Ahmed Ph.D. will test her vectors for efficacy in the USH1F mouse model. 
Dr. Leah Byrne's Lab Page


Developing Several Approaches to Gene Therapy for USH1F

Research Continuum Graphic: Research in Basic/Translational stage. Highlighted in yellow: Basic/Translational. All other subsequent sections shown in grey: Pre-Clinical, Clinical Trials Phase I, Phase II, and Phase III, and Treatments-Phase IV.
Profile Picture of Dr. David Corey

David Corey, Ph.D.: 
Harvard Medical School
Corey and his team at Harvard Medical School have spent years studying protocadherin 15, the USH1F gene, in relation to hearing. have decided to pursue research on treating the vision loss of USH1F after attending Usher 1F Collaborative's May 2017 researchers symposium. Dr. Corey and his team are working on three approaches to gene therapy: mini genes, split genes, and gene editing. He has begun testing of mini genes for efficacy in the zebrafish from the Westerfield Lab. 
Dr. David Corey's Lab Page


Gene Editing for USH1F

Research Continuum Graphic: Research in Basic/Translational stage. Highlighted in yellow: Basic/Translational. All other subsequent sections shown in grey: Pre-Clinical, Clinical Trials Phase I, Phase II, and Phase III, and Treatments-Phase IV.
Profile Picture of Dr. Alex Hewitt

Alex Hewitt, Ph.D.: 
Center Eye Research Australia
Hewitt and team at the Center Eye Research Australia (CERA) have obtained a grant from the Australian government to support his USH1F research. Utilizing this money, he is working on gene editing to effectively treat the vision loss of Usher 1F.


Function of Usher Syndrome protein PCDH15 in photoreceptor maintenance

Research Continuum Graphic: Research in Basic/Translational stage. Highlighted in yellow: Basic/Translational. All other subsequent sections shown in grey: Pre-Clinical, Clinical Trials Phase I, Phase II, and Phase III, and Treatments-Phase IV.
Profile Picture of Dr. Vincent Tropepe

Vincent Tropepe Ph.D.:
University of Toronto
Vincent Tropepe and his lab investigate how neurogenesis contributes to the generation and maintenance of regional nerve cell diversity throughout life. Dr.Tropepe has received funding from the Fighting Blindness Canada to conduct research using zebrafish to study Usher 1F.
Dr. Vincent Tropepe's Lab Page
Link to Relevant Publication


USH1F-Related Science News

 

The Bertarelli Foundation has awarded collaborative research grants to four teams of scientists from Harvard Medical School (HMS) and the Institute of Molecular and Clinical Ophthalmology in Basel, Switzerland, all focused on understanding and treating some of the most devastating sensory disorders such as Usher syndrome. Two HMS neurobiologists, studying the origins of deafness—David Corey and Arthur Indzhykulian—are joining forces with Botond Roska, an expert on retinal biology and eye disease at the Institute of Molecular and Clinical Ophthalmology in Basel, Switzerland to develop treatments for Usher syndrome type 1F. The researchers will focus on developing gene therapy aimed at overcoming a hurdle that has hindered therapeutic efforts so far: the unusually large Usher 1F protein.

What this means for Usher syndrome: This research could open the door for development of therapies to treat Usher 1F.

Jennifer Phillips, Ph.D." on defining “Failure”: Disclosing when things don’t work and understanding WHY is a really important, though often overlooked realm of research. Here are a couple of USH1 research stories from today’s presentations that illustrate that point.

Powered by Firespring